Related Experiment Video
Updated: May 14, 2026
09:28
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 25, 2010
Newborn screening for citrin deficiency and carnitine uptake defect using second-tier molecular tests
Li-Yun Wang1, Nien-I Chen, Pin-Wen Chen
1Graduate Institute of Molecular Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
BMC Medical Genetics
|February 12, 2013
Summary
A second-tier molecular test improves newborn screening for citrin deficiency and carnitine uptake defect (CUD) by increasing sensitivity without raising false positives. This method is feasible for early detection of these rare metabolic disorders.
Area of Science:
- Biochemistry
- Genetics
- Neonatal Medicine
Background:
- Tandem mass spectrometry (MS/MS) is crucial for newborn screening of inborn errors of metabolism.
- Current MS/MS screening has suboptimal sensitivity for citrin deficiency and carnitine uptake defect (CUD).
Purpose of the Study:
- To evaluate if a second-tier molecular test enhances detection sensitivity for citrin deficiency and CUD.
- To assess if this molecular approach increases the false-positive rate in newborn screening.
Main Methods:
- Analyzed mutations in SLC25A13 (citrin deficiency) and SLC22A5 (CUD) genes.
- Targeted newborns with inconclusive primary MS/MS screening results.
Main Results:
- Identified two patients with citrin deficiency (1:23,350) and one with CUD (1:30,000) via second-tier testing.
- The molecular test improved sensitivity for both conditions without increasing false positives.
Conclusions:
- A molecular second-tier test is a feasible strategy for improving newborn screening.
- This approach enhances the detection of citrin deficiency and carnitine transporter deficiency.
